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Abstract. The prognostic and predictive value of pre-treatment 
serum levels of carcinoembryonic antigen (CEA) and cyto-
keratin-19 fragments (CYFRA 21-1) were assessed in advanced 
non-small cell lung cancer (NSCLC) patients treated with gefi-
tinib or erlotinib. Pre-treatment CEA and CYFRA 21-1 levels 
were measured in 123 advanced NSCLC patients receiving 
gefitinib or erlotinib. High CEA levels (h-CEA) were signifi-
cantly associated with females, patients with adenocarcinoma 
and non-smokers. Low CYFRA 21-1 levels (l-CYFRA 21-1) 
were significantly associated with a good performance status 
(ECOG PS 0-1). The overall response rate (RR) was 27.6%, and 
a higher RR was associated with adenocarcinoma, h-CEA, and 
epidermal growth factor receptor (EGFR) mutation. Patients with 
h-CEA had significantly longer progression-free survival (PFS) 
(P=0.021). Patients with l-CYFRA 21-1 had significantly longer 
PFS and overall survival (OS) (P=0.006 and P<0.001, respec-
tively). Notably, h-CEA and l-CYFRA 21-1 levels were associated 
with good prognosis in patients with unknown EGFR mutation 
status or patients with squamous cell carcinoma (P=0.021 and 
P=015, respectively). A good ECOG PS (HR=0.45, P=0.017), 
h-CEA (HR=0.41, P=0.007), l-CYFRA 21-1 (HR=0.52, 
P=0.025), and an EGFR mutation (HR=0.22, P<0.001) were 
independently predictive of a longer PFS. A good ECOG PS 
(HR=0.52, P=0.018), l-CYFRA 21-1 (HR=0.36, P=0.004), and 
EGFR mutation (HR=0.53, P=0.051) were independently predic-
tive of longer OS. h-CEA and l-CYFRA 21-1 may be prognostic 
and predictive serum markers for higher response and longer 
survival in patients with advanced NSCLC receiving gefitinib or 
erlotinib, particularly in patients with unknown EGFR mutation 
status or patients with squamous cell carcinoma.
Introduction
Lung cancer is the leading cause of cancer-related mortality in 
the world. Non-small cell lung cancer (NSCLC) accounts for 
approximately 85% of all lung cancer cases (1). The oral small 
molecule epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs), such as gefitinib and erlotinib, promote 
responses in 10-18% of patients who had a failed response to prior 
chemotherapy. Erlotinib was found to have a 2-month median 
survival advantage over a placebo (2), and gefitinib did not exhibit 
an inferior efficacy when compared with docetaxel (3).
Treatment with an EGFR TKI is effective in women, 
Asians, non-smokers, and patients with adenocarcinoma. An 
EGFR mutation was found to be the most important predic-
tive factor for patient response to an EGFR TKI (4). However, 
acquiring adequate tissue for an EGFR mutational analysis 
is often not feasible, particularly in patients with advanced 
disease (2-4). Therefore, the identification of clinical param-
eters that can serve as surrogates markers for an EGFR 
mutation may prove useful when mutational analysis is not 
feasible. A recent study reported that the molecular analysis 
of circulating tumor cells from the peripheral blood of 
patients with lung cancer was useful in monitoring changes in 
epithelial tumor genotypes during the course of treatment (5). 
However, this molecular analysis may prove to be difficult as a 
specific microfluidic-based device, the CTC chip, is required.
Therefore, a marker that is easily analyzed and predicts the 
responses to EGFR TKI treatment is needed. Several serum 
markers have been considered potentially prognostic and 
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predictive in NSCLC. Among these NSCLC markers, carci-
noembryonic antigen (CEA) and cytokeratin-19 fragments 
(CYFRA 21-1) have been considered sensitive and valuable 
tumor markers for diagnosis, prognosis, and the monitoring 
of therapy (6-10). According to recent reports, CEA and 
CYFRA 21-1 were significant predictors of sensitivity and 
survival in patients treated with gefitinib (11-13). Therefore, 
we investigated the clinical significance of the pre-treatment 
serum levels of CEA and CYFRA 21-1 in advanced NSCLC 
patients who were treated with gefitinib or erlotinib.
Materials and methods
We retrospectively collected clinical data on 123 NSCLC 
patients whose pre-treatment levels of CEA and CYFRA 21-1 
had been measured and who received gefitinib or erlotinib 
treatment at Severance Hospital, Yonsei University Health 
System, Seoul, Korea, from January 2006 to December 
2008. Variables used in the pre-treatment analysis were age, 
gender, clinical stage, Eastern Cooperative Oncology Group 
(ECOG) performance status (PS), histological type, smoking 
history, number of prior chemotherapy regimens, and EGFR 
mutation if possible. Serum CEA (normal range, 0-5 ng/
ml) and CYFRA 21-1 (normal range, 0-3.3 ng/ml) were 
measured using a chemiluminescence enzyme immunoassay 
kit (Beckman Coulter, MN, USA) and an electrochemilumi-
nescence immunoassay on an automatic analyzer (Elecsys 
200; Roche Diagnostics Mannheim, Basel, Switzerland), 
respectively, before TKI treatment. Histological analysis of 
the tumors was based on the WHO classification of cell types 
Table I. Comparison of pre-treatment clinicopathological characteristics according to CEA and CYFRA 21-1 levels.
 CEA, n (%) CYFRA 21-1, n (%)
 ----------------------------------------------------------------------- -------------------------------------------------------------------------------
Patient characteristics n (%) <5 ng/ml ≥5 ng/ml P-value <3.3 ng/ml ≥3.3 ng/ml P-value
Total 123 (100) 53 (43.1) 70 (56.9)  59 (48) 64 (52)
Age (years)
Median (range) 55 (34-88)   0.265   0.451
  <65 81 (65.9) 32 (39.5) 49 (60.5)  41 (50.6) 40 (49.4)
  ≥65 42 (34.1) 21 (50.0) 21 (50.0)  18 (42.9) 24 (57.1)
Gender    <0.001   0.192
  Male 70 (56.9) 40 (57.2) 30 (42.9)  30 (42.9) 40 (57.1)
  Female 53 (43.1) 13 (24.5) 40 (75.5)  29 (54.7) 24 (45.3)
Histologic type    0.043   0.995
  Adenocarcinoma 73 (59.3) 26 (35.6) 47 (64.4)  35 (47.9) 38 (52.1)
  Non-adenocarcinoma 50 (40.7) 27 (54.0) 23 (46.0)  24 (48.0) 52 (52.0)
Clinical stage    0.439   0.628
  IIIB 35 (18.5) 17 (48.6) 18 (51.4)  18 (51.4) 17 (48.6)
  IV 88 (71.5) 36 (40.9) 52 (59.1)  41 (46.6) 47 (53.4)
Performance status    0.100   0.017
  0-1 83 (67.5) 40 (48.2) 43 (51.8)  46 (55.4) 37 (44.6)
  2 40 (32.5) 13 (32.5) 27 (67.5)  13 (32.5) 27 (67.5)
Smoking history    0.036   0.072
  None 59 (47.5) 19 (32.8) 39 (67.2)  33 (56.9) 25 (43.1)
  Current + former 64 (52.5) 33 (51.6) 31 (48.2)  26 (40.6) 38 (59.4)
No. of prior regimens    0.631   0.485
  ≤1 40 (32.5) 16 (40.0) 24 (60.0)  21 (52.5) 19 (47.5)
  ≥2 83 (67.5) 37 (44.6) 46 (55.4)  38 (45.8) 45 (54.2)
TKI    0.669   0.203
  Gefitinib 72 (58.5) 29 (40.3) 43 (61.4)  37 (51.4) 35 (48.6)
  Erlotinib 51 (41.5) 24 (47.1) 27 (52.9)  22 (43.1) 29 (56.9)
EGFR mutation (n=84)    0.418   0.789
  Negative 47 (38.2) 19 (40.4) 28 (59.6)  23 (48.9) 24 (51.1)
  Positive 37 (30.1) 14 (37.8) 23 (62.2)  19 (51.4) 18 (48.6)
  Unknown 39 (31.7) 20 (51.3) 19 (48.7)  17 (43.6) 22 (56.4)
CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor 
receptor
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(14). The clinical response to the drug was defined according 
to the response evaluation criteria of RECIST 1.0 for patients 
with measurable disease (15). Nucleotide sequencing of the 
kinase domain of EGFR (exons 18 to 21) was performed 
using nested polymerase chain reaction (PCR) amplification 
of individual exons. The details of sequencing have been 
described previously (16). This study was approved by the 
Institutional Review Board of the Yonsei University Health 
System (approval no. 4-2009-0700).
Statistical methods. The association between pre-treatment 
levels of CEA and CYFRA 21-1 and other categorical clinical 
variables were compared using the Pearson's Chi-square test. 
Progression-free survival (PFS) was defined as the time from 
the start day of TKI treatment until the date of tumor progres-
sion or death. Overall survival (OS) was measured from the 
date of diagnosis to the date of death or final follow-up. The 
survival data were estimated using a Kaplan-Meier curve 
and compared using the log-rank test. Multivariate analyses 
were performed to find prognostic markers using Cox's 
proportional hazards model. A P-value <0.05 was considered 
statistically significant.
Results
Patient characteristics. The clinicopathological char-
acteristics of the 123 patients are summarized in Table I. 
Notably, a a high serum CEA (h-CEA) level (≥5 ng/ml) 
was observed in 70 (56.9%) patients, and was significantly 
more frequent in females, patients with adenocarcinoma 
and patients without a history of smoking. On the other 
hand, 64 (52%) patients had an elevated serum CYFRA 21-1 
(h-CYFRA 21-1) level (≥3.3 ng/ml), which was significantly 
more frequent in patients with a poor ECOG PS (P=0.017) 
and in those with a history of smoking (P=0.072). There 
was no difference in either CEA or CYFRA 21-1 levels in 
terms of EGFR mutation status.
Association of serum markers with responses to EGFR 
TKIs. The median follow-up duration was 9.0 months (range, 
0.2-43 months). The median PFS was 5.0 months (95% CI, 
3.3-6.7 months), and the median OS was 16.0 months (95% 
CI, 8.7-23.3 months). Responses were not assessable in 
7 patients; 4 patients died and 3 patients refused treatment 
before response evaluation. Thirty-two of the evaluable 116 
(27.6%) patients showed partial responses. The response 
rate to EGFR TKIs was significantly higher in patients with 
adenocarcinoma, an EGFR mutation, and a h-CEA (≥5 ng/
ml) serum level. The disease control rate in the patients with 
h-CEA levels was significantly higher than those with low 
CEA (l-CEA) levels (75 vs. 51.9%, P=0.034). There were no 
differences in the response rates according to gender, smoking 
history, or the number of prior chemotherapy regimens. There 
was a trend towards a better response rate in patients with 
Figure 1. Progression-free survival (PFS) curves according to pre-treatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments 
(CYFRA 21-1). (A) CEA. (B) CYFRA 21-1. (C) Combinations of CEA and CYFRA 21-1 by group: (a) patients with l-CEA and h-CYFRA 21-1, (b) patients with 
l-CEA and l-CEA or h-CEA and h-CYFRA 21-1 and (c) patients with a h-CEA and l-CYFRA 21-1.
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low CYFRA 21-1 (l-CYFRA) levels (P=0.104). To evaluate 
whether the combination of CEA and CYFRA 21-1 levels 
improved the prediction accuracy, patients were divided 
into three groups according to their CEA and CYFRA 21-1 
levels. Patients with a l-CEA and a h-CYFRA 21-1 level were 
defined as group A (CEA <5 ng/ml and CYFRA 21-1 ≥3.3 ng/
ml, n=24), while those with l-CEA and l-CYFRA 21-1 levels 
or h-CEA and h-CYFRA 21-1 levels were considered group B 
(CEA <5 ng/ml and CYFRA 21-1 <3.3 ng/ml, or CEA ≥5 ng/
ml and CYFRA 21-1 ≥3.3 ng/ml, n=66). Finally, patients with 
h-CEA and l-CYFRA 21-1 levels were defined as group C 
(CEA ≥5 ng/ml and CYFRA 21-1 <3.3 ng/ml, n=26). The 
three groups showed significantly different response rates, 
with the most favorable responses noted in group C (42.3 vs. 
25.8 vs. 16.7%, P=0.005, for groups C, B and A, respectively) 
(Table II).
Association of serum markers with survival. Patients with a 
h-CEA level had significantly better PFS than those with a 
l-CEA level (7.0 vs. 4.0 months, P=0.021). In contrast, patients 
with a l-CYFRA 21-1 level also had significantly better PFS 
than those with h-CYFRA 21-1 (8.1 vs. 3.0 months, P=0.006). 
Table II. Comparison of pretreatment clinicopathological characteristics according to EGFR TKI responses.
Patient characteristics PR, n (%) SD, n (%) PD, n (%) P-value
Total (n=116) 32 (27.6) 43 (37.1) 41 (35.3)
Age (years)
  <65  20 (25.6) 31 (39.8) 27 (34.6) 0.663
  ≥65 12 (31.6) 12 (31.6) 14 (36.8)
Gender
  Male 16 (24.2) 28 (42.4) 22 (33.4) 0.371
  Female 16 (32.0) 15 (30.0) 19 (38.0)
Histologic type
  Adenocarcinoma 25 (35.2) 19 (26.8) 27 (38.0) 0.009
  Non-adenocarcinoma   7 (15.6) 24 (53.3) 14 (31.1)
Performance status
  0-1 26 (32.9) 30 (38.0) 23 (29.1) 0.07
  2   6 (16.2) 13 (35.2) 18 (48.6)
Smoking history
  None 17 (30.9) 18 (32.7) 20 (36.4) 0.673
  Current + former 15 (25.0) 24 (40.0) 21 (35.0)
No. of prior regimens
  ≤1 13 (35.1) 13 (35.1) 11 (29.8) 0.436
  ≥2 19 (24.1) 30 (38.0) 30 (38.0)
Serum CEA level (ng/ml)
  <5  11 (21.1) 16 (30.8) 25 (48.1) 0.034
  ≥5 21 (32.8) 27 (42.2) 16 (25.0)
Serum CYFRA 21-1 level (ng/ml)
  <3.3  18 (32.7) 23 (41.8) 14 (25.5) 0.104
  ≥3.3  14 (23.0) 20 (32.8) 27 (44.2)
Combination of CEA and 
CYFRA 21-1
  Group C 11 (42.3) 12 (46.2)   3 (11.5) 0.005
  Group B 17 (25.8) 26 (39.4) 23 (34.8)
  Group A   4 (16.7)   5 (20.8) 15 (62.5)
EGFR mutation (n=84)
  Negative   7 (15.6) 12 (26.7) 26 (57.8) <0.001
  Positive 18 (52.9) 10 (29.4)   6 (17.6)
Group A, CEA <5 and CYFRA 21-1 ≥3.3 ng/ml. Group B, CEA <5 and CYFRA 21-1 <3.3 or CEA ≥5 and CYFRA 21-1 ≥3.3 ng/ml. Group C, 
CEA ≥5 and CYFRA 21-1 <3.3 ng/ml. PR, partial remission; SD, stable disease; PD, progression of disease; CEA, carcinoembryonic antigen; 
CYFRA 21-1, cytokeratin-19 fragments; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor.
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When subgrouped by combined CEA and CYFRA 21-1 
levels, the three groups showed significantly different PFS, 
and group C showed the longest PFS among the three groups 
(15.0 vs. 4.0 vs. 2.0 months, P<0.001, for groups C, B and A, 
respectively) (Fig. 1). Particularly, group C had the longest PFS 
among the patients with squamous cell carcinoma (Fig. 2). In 
addition, a h-CEA and a l-CYFRA 21-1 level was a significant 
prognostic marker, not only in patients with EGFR-mutant 
Table III. Univariate predictions of survival.
 PFS OS
 --------------------------------------------------------------------------- ----------------------------------------------------------------------------
Category Median 95% CI P-value Median 95% CI P-value
 (months)   (months)
Total 5.0 3.3-6.7  16.0 8.7-23.3
Age (years)
  <65 4.1 2.0-6.2 0.982 15.1 10.5-19.7 0.843
  ≥65 5.6 2.8-8.4  22.0 5.5-38-5
Gender
  Male 4.1 2.7-5.6 0.985 15.1 9.3-20.9 0.902
  Female 6.0 2.5-9.50  18.1 5.7-30.6
Histologic type
  Adenocarcinoma 5.6 3.3-7.8 0.942 18.1 0.0-36.3 0.716
  Non-adenocarcinoma 4.1 1.2-7.0  16.0 8.3-23.7
Performance status
  0-1 6.1 3.2-9.0 0.016 29.6 19.9-39.4 <0.001
  2 3.0 1.0-5.0  6.1 1.7-10.6
Smoking history
  None 5.0 2.8-7.2 0.331 16.0 7.0-25.0 0.780
  Current + former 4.9 3.1-6.7  14.1  1.7-26.5
No. of prior regimens
  0-1 8.1 3.2-13.0 0.176 29.6 3.3-55.3 0.447
  ≥ 2 4.0 2.0-6.0  15.0 9.1-20.9
TKI
  Gefitinib 5.6 3.6-7.5 0.679 16.0 8.9-23.1 0.935
  Erlotinib 3.9 1.5-6.3  24.0 13.2-34.9
Serum CEA level (ng/ml)
  <5 4.0 1.7-6.3 0.021 14.0 2.2-25.8 0.505
  ≥5 7.0 2.5-11.5  18.0 10.3-25.7
Serum CYFRA 21-1 level (ng/ml)
  <3.3 8.1 2.9-13.3 0.006 NR  <0.001
  ≥3.3 3.0 2.0-4.0  8.0 5.2-10.8
Combination of CEA and
CYFRA 21-1 (ng/ml)
  CEA ≥5 and CYFRA 21-1 <3.3 15.0 5.7-24.3 <0.001 NR  0.002
  CEA <5 and CYFRA 21-1 <3.3 or 4.0 3.1-4.9  14.1 5.0-23.2
  CEA ≥5 and CYFRA 21-1 ≥3.3
  CEA <5 and CYFRA 21-1 >3.3 2.0 0.9-3.1  8.0 4.8-11.2
EGFR mutation (n=84)
  Negative 2.0 1.4-2.7 <0.001 7.1 3.9-10.3 0.038
  Positive 11.0  5.3-16.7  22.0 13.1-31.0
PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor; CEA, carcinoembryonic antigen; CYFRA 21-1, cytok-
eratin-19 fragments; NR, not reached; EGFR, epidermal growth factor receptor.
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tumors, but in patients with an unknown EGFR mutation 
status (Fig. 3). Finally, univariate analysis revealed several 
significant factors for PFS including good ECOG PS (6.1 vs. 
3.0 months, P=0.016) and positive EGFR mutation status (11.0 
vs. 2.0 months, P<0.001) (Table III).
Patients with good ECOG PS and a positive EGFR muta-
tion status also had significantly longer OS than those who 
had a poor ECOG PS and a negative EGFR mutation status 
(ECOG PS, 29.6 vs. 6.1 months, P<0.001; EGFR mutation 
status, 22.0 vs. 7.1 months, P=0.038, respectively). However, 
OS did not differ according to pre-treatment CEA levels. 
Patients with a l-CYFRA 21-1 level had a longer OS than 
those with h-CYFRA 21-1 (not reached vs. 8.0 months, 
P<0.001). Patients in group C also had the longest OS among 
the three groups (Table IV and Fig. 4).
Multivariate analysis using a Cox proportional hazards 
model indicated that a good ECOG PS, positive EGFR 
mutation status, high pre-treatment CEA levels, and low 
pre-treatment CYFRA 21-1 levels are independent predic-
tive factors for PFS. Meanwhile, predictive factors for OS 
Figure 2. Progression-free survival (PFS) curves according to pre-treatment serum levels of a combination of carcinoembryonic antigen (CEA) and cyto-
keratin-19 fragments (CYFRA 21-1) according to histologic type. (a) Patients with l-CEA and h-CYFRA 21-1, (b) patients with l-CEA and l-CYFRA 21-1 or 
h-CEA and h-CYFRA 21-1 and (c) patients with h-CEA and l-CYFRA 21-1. (A) Patients with adenocarcinoma. (B) Patients with squamous cell carcinoma.
  B  A
Figure 3. Progression-free survival (PFS) curves according to pre-treatment serum levels of a combination of carcinoembryonic antigen (CEA) and cyto-
keratin-19 fragments (CYFRA 21-1) according to epidermal growth factor receptor (EGFR) mutation status. (a) Patients with l-CEA and h-CYFRA 21-1, (b) 
patients with l-CEA and l-CYFRA 21-1 or h-CEA and h-CYFRA 21-1 and (c) patients with h-CEA and l-CYFRA 21-1. (A) Patients with a negative EGFR 
mutation. (B) Patients with a positive EGFR mutation. (C) Patients with unknown EGFR mutation status.
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Table IV. Multivariate predictions of survival.
 PFS OS
 ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------
Category Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (years)
  <65 vs. ≥65 1.23 0.67-2.28 0.506 1.18 0.64-2.29 0.633
Gender
  Female vs. male 2.86 0.75-10.89 0.124 1.24 0.27-6.75 0.808
Histologic type
  Non-adeno vs. adeno 0.80 0.41-1.56 0.521 1.59 0.81-3.14 0.182
Clinical stage
  IV vs. III 0.64 0.35-1.15 0.134 0.80 0.40-1.60 0.534
Performance status
  0-1 vs. 2 2.02 1.13-3.61 0.017 2.13 1.14-3.98 0.018
Smoking history
  None vs. current + former 1.48 0.39-5.56 0.57 1.38 0.25-7.61 0.706
Serum CEA level (ng/ml)
  <5 vs. ≥5 0.41 0.24-0.78 0.007 0.55 0.25-1.21 0.554
Serum CYFRA 21-1 level (ng/ml)       
  <3.3 vs. ≥3.3 1.93 1.09-3.44 0.025 2.76 1.38-5.53 0.004
EGFR mutation (n=84)
  Negative vs. positive 0.22 0.11-0.42 <0.001 0.53 0.28-1.004 0.051
PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor; CEA, carcinoembryonic antigen; CYFRA 21-1, cytok-
eratin-19 fragments; EGFR, epidermal growth factor receptor.
Figure 4. Overall survival (OS) curves according to pre-treatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments 
(CYFRA 21-1). (A) CEA. (B) CYFRA 21-1. (C) Combinations of CEA and CYFRA 21-1 by group: (a) patients with l-CEA and h-CYFRA 21-1, (b) patients 
with l-CEA and l-CYFRA 21-2 or h-CEA and h-CYFRA 21-1 and (c) patients with h-CEA and l-CYFRA 21-1.
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included a good ECOG PS, positive EGFR mutation status 
and l-CYFRA 21-1, but not h-CEA (Table IV).
Discussion
Detection of a mutation in the EGFR gene in NSCLC patients 
treated with an EGFR TKI is the most important factor for 
the prediction of a good response to these drugs (4). However, 
the detection of an EGFR mutation may be difficult due to the 
limited amount of available tissue (2-4). Therefore, a surro-
gate biomarker that can improve the prediction of response to 
these targeted drugs is needed.
CEA was first described by Gold and Freedman in 1965 
as an antigen expressed by gastrointestinal carcinoma cells 
(17). Although CEA was often falsely elevated in smokers and 
in patients with restrictive or obstructive pulmonary disease 
(18-20), abnormally elevated CEA levels were reported in 
30-70% of patients with NSCLC and were most frequently 
observed in patients with adenocarcinoma and advanced stage 
carcinoma (21). In addition, several studies have shown that 
h-CEA is a potential marker of poor prognosis in NSCLC 
regardless of treatment (7,21).
On the contrary, Okamoto et al (11) reported that patients 
treated with EGFR TKIs with high pre-treatment levels of 
CEA had a longer survival and a better response than those 
with l-CEA. They attributed this to a possible anti-apoptotic 
signal of the mutant EGFR pathway that may elevate the 
expression level of CEA protein. Our data are similar to the 
data of Okamato et al (11). Shoji et al (22) reported that the 
rate of the EGFR gene mutation significantly increased as 
the serum CEA level increased (for serum CEA levels of <5, 
≥5 but <20, and ≥20, the rate of the EGFR gene mutation 
was 35, 55 and 87.5%, respectively; P=0.040). However, our 
data showed that the status of the EGFR mutation made no 
difference in the CEA levels. Based on previous reports, the 
function of CEA has not been elucidated but may include the 
following: i) CEA is a cell surface adhesion protein and may 
play a role in cell-to-cell adhesion (23); ii) overexpression of 
CEA is thought to play a role in tumorigenesis (24); iii) CEA 
has a dominant effect in blocking differentiation, and it also 
cooperates with Myc and Bcl-2 in cellular transformation (25); 
and iv) it can inhibit cell death induced by a loss of anchorage 
to the extracellular matrix (anoikis) (26). Although these find-
ings suggest that CEA has anti-apoptotic effects in cancer 
cells, a direct relationship between h-CEA and response to 
EGFR TKIs has not yet been established.
CYFRA 21-1, a fragment of cytokeratin subunit 19, was 
first identified in 1993 as a valuable marker in lung cancer 
patients (27). CYFRA 21-1 was found to be associated with 
TNM stage and ECOG PS, reflecting an unfavorable prog-
nosis for NSCLC patients regardless of treatment (8,21,28-30). 
In our study, patients with a poor ECOG PS had a higher 
CYFRA 21-1 level than patients with a good ECOG PS (6.4 
vs. 3.0 ng/ml; P=0.03). Patients with h-CYFRA 21-1 levels 
were more likely to have a history of smoking; however, this 
association was not significant (P=0.072). Previous studies 
have also reported that smoking has no effect on serum 
CYFRA 21-1 levels (31,32). Univariate and multivariate anal-
yses demonstrated that CYFRA 21-1 levels higher than 3.3 ng/
ml had an independent negative impact on PFS (HR=1.93, 
95% CI 1.09-3.44;  P=0.025) and OS (HR=2.76, 95% CI 1.38-
5.53; P=0.0004). Therefore, CYFRA 21-1 is an independent 
marker for poor prognosis in NSCLC patients receiving an 
EGFR TKI, which is consistent with a previous study (12).
We demonstrated that pre-treatment levels of CEA and 
CYFRA 21-1 serve as prognostic and predictive markers in 
NSCLC patients treated with gefitinib or erlotinib. Patients 
with a high pre-treatment CEA level showed better responses 
and longer PFS, and patients with a low pre-treatment 
CYFRA 21-1 level showed longer PFS and OS. In addition, the 
prediction accuracy of the EGFR TKI response and prognosis 
improved when all patients were divided into three groups 
according to combined levels of CEA and CYFRA 21-1. 
It is difficult to predict high efficacy of EGFR TKIs when 
they are used in patients with non-adenocarcinoma histology 
since the incidence of EGFR mutation is extremely rare in 
these tumors (33). However, the present study revealed that 
CEA and CYFRA 21-1 levels can also be prognostic markers 
in patients with squamous cell carcinoma or patients with 
unknown EGFR mutation status (Figs. 2 and 3).
In conclusion, pre-treatment serum levels of CEA and 
CYFRA 21-1 are simple and easy to detect, and can serve 
as predictive and prognostic factors for advanced NSCLC 
patients being treated with EGFR TKIs, particularly in 
patients with squamous cell carcinoma or patients with an 
unknown EGFR mutation status.
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